{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:59:13Z","timestamp":1785131953338,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12185-026-04207-0","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T10:38:05Z","timestamp":1775558285000},"page":"238-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ten-color multicolor flow cytometry-based measurable residual disease at pre-transplantation predicts relapse of acute myeloid leukemia: a prospective study"],"prefix":"10.1007","volume":"124","author":[{"given":"Kumiyo","family":"Tazoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4203-990X","authenticated-orcid":false,"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Makuuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhito","family":"Takakuwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asao","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutaka","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"issue":"5","key":"4207_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1399-0039.2006.00714.x","volume":"68","author":"N-G Chung","year":"2006","unstructured":"Chung N-G, Buxhofer-Ausch V, Radich JP. The detection and significance of minimal residual disease in acute and chronic leukemia. Tissue Antigens. 2006;68(5):371\u201385. https:\/\/doi.org\/10.1111\/j.1399-0039.2006.00714.x.","journal-title":"Tissue Antigens"},{"issue":"2","key":"4207_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1182\/blood-2011-08-363291","volume":"119","author":"F Buccisano","year":"2012","unstructured":"Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2012;119(2):332\u201341. https:\/\/doi.org\/10.1182\/blood-2011-08-363291.","journal-title":"Blood"},{"issue":"12","key":"4207_CR3","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020;6(12):1890\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4600.","journal-title":"JAMA Oncol"},{"issue":"8","key":"4207_CR4","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1182\/blood-2007-11-120535","volume":"111","author":"FE Craig","year":"2008","unstructured":"Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111(8):3941\u201367. https:\/\/doi.org\/10.1182\/blood-2007-11-120535.","journal-title":"Blood"},{"issue":"16","key":"4207_CR5","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132(16):1703\u201313. https:\/\/doi.org\/10.1182\/blood-2018-02-829911.","journal-title":"Blood"},{"issue":"31","key":"4207_CR6","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1200\/jco.2009.22.4865","volume":"27","author":"D Cilloni","year":"2009","unstructured":"Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27(31):5195\u2013201. https:\/\/doi.org\/10.1200\/jco.2009.22.4865.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4207_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/ejh.13664","volume":"107","author":"C Rautenberg","year":"2021","unstructured":"Rautenberg C, Lauseker M, Kaivers J, J\u00e4ger P, Fischermanns C, Pechtel S, et al. Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS. Eur J Haematol. 2021;107(2):283\u201392. https:\/\/doi.org\/10.1111\/ejh.13664.","journal-title":"Eur J Haematol"},{"issue":"1","key":"4207_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3892\/etm.2011.363","volume":"3","author":"J Pol\u00e1k","year":"2012","unstructured":"Pol\u00e1k J, H\u00e1jkov\u00e1 H, Maalaufov\u00e1-Soukupov\u00e1 J, Markov\u00e1 J, S\u00e1lek C, Schwarz J, et al. Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression. Exp Ther Med. 2012;3(1):129\u201333. https:\/\/doi.org\/10.3892\/etm.2011.363.","journal-title":"Exp Ther Med"},{"issue":"5","key":"4207_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/bmt.2014.9","volume":"49","author":"C Anthias","year":"2014","unstructured":"Anthias C, Dignan FL, Morilla R, Morilla A, Ethell ME, Potter MN, et al. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. Bone Marrow Transplant. 2014;49(5):679\u201383. https:\/\/doi.org\/10.1038\/bmt.2014.9.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"4207_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/ajh.21340","volume":"84","author":"M D\u00edez-Campelo","year":"2009","unstructured":"D\u00edez-Campelo M, P\u00e9rez-Sim\u00f3n JA, P\u00e9rez J, Alcoceba M, Richtmon J, Vidriales B, et al. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Am J Hematol. 2009;84(3):149\u201352. https:\/\/doi.org\/10.1002\/ajh.21340.","journal-title":"Am J Hematol"},{"issue":"9","key":"4207_CR11","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1200\/jco.2010.31.8121","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29(9):1190\u20137. https:\/\/doi.org\/10.1200\/jco.2010.31.8121.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4207_CR12","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.3324\/haematol.2017.167254","volume":"102","author":"F Guolo","year":"2017","unstructured":"Guolo F, Minetto P, Clavio M, Miglino M, Galaverna F, Raiola AM, et al. Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia. Haematologica. 2017;102(9):e348\u201351. https:\/\/doi.org\/10.3324\/haematol.2017.167254.","journal-title":"Haematologica"},{"issue":"5","key":"4207_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/ejh.13694","volume":"107","author":"F Guolo","year":"2021","unstructured":"Guolo F, Di Grazia C, Minetto P, Raiola AM, Clavio M, Miglino M, et al. Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. Eur J Haematol. 2021;107(5):573\u201382. https:\/\/doi.org\/10.1111\/ejh.13694.","journal-title":"Eur J Haematol"},{"issue":"23","key":"4207_CR14","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664\u201371. https:\/\/doi.org\/10.1182\/blood-2014-01-552984.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4207_CR15","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1182\/blood-2022-164739","volume":"140","author":"MJ Hochman","year":"2022","unstructured":"Hochman MJ, Othus M, Hasserjian RP, Ambinder AJ, Brunner AM, Percival M-EM, et al. Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification. Blood. 2022;140(Supplement 1):1430\u20132. https:\/\/doi.org\/10.1182\/blood-2022-164739.","journal-title":"Blood"},{"issue":"1","key":"4207_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12185-015-1882-1","volume":"103","author":"K Kitamura","year":"2016","unstructured":"Kitamura K, Nishiyama T, Ishiyama K, Miyawaki S, Miyazaki K, Suzuki K, et al. Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood. Int J Hematol. 2016;103(1):53\u201362. https:\/\/doi.org\/10.1007\/s12185-015-1882-1.","journal-title":"Int J Hematol"},{"issue":"12","key":"4207_CR17","first-page":"1279","volume":"46","author":"S Miyawaki","year":"2005","unstructured":"Miyawaki S, Emi N, Mitani K, Oyashiki K, Kitamura K, Morishita T, et al. Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan. Rinsho Ketsueki. 2005;46(12):1279\u201387.","journal-title":"Rinsho Ketsueki"},{"issue":"12","key":"4207_CR18","first-page":"1748","volume":"51","author":"K Kitamura","year":"2010","unstructured":"Kitamura K, Nakano Y, Watamoto K, Koga D, Naoe T. [Significance of monitoring WT1 mRNA levels of peripheral blood and bone marrow in acute myeloid leukemia]. Rinsho Ketsueki. 2010;51(12):1748\u201355.","journal-title":"Rinsho Ketsueki"},{"issue":"9","key":"4207_CR19","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/leu.2012.120","volume":"26","author":"JJM van Dongen","year":"2012","unstructured":"van Dongen JJM, Lhermitte L, B\u00f6ttcher S, Almeida J, van der Velden VHJ, Flores-Montero J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908\u201375. https:\/\/doi.org\/10.1038\/leu.2012.120.","journal-title":"Leukemia"},{"issue":"3","key":"4207_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.cll.2007.05.006","volume":"27","author":"BL Wood","year":"2007","unstructured":"Wood BL. Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia. Clin Lab Med. 2007;27(3):551\u201375. https:\/\/doi.org\/10.1016\/j.cll.2007.05.006.","journal-title":"Clin Lab Med"},{"issue":"3","key":"4207_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"4207_CR22","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/ejh.13557","volume":"106","author":"E Klyuchnikov","year":"2021","unstructured":"Klyuchnikov E, Christopeit M, Badbaran A, Bacher U, Fritzsche-Friedland U, von Pein U-M, et al. Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML. Eur J Haematol. 2021;106(5):606\u201315. https:\/\/doi.org\/10.1111\/ejh.13557.","journal-title":"Eur J Haematol"},{"issue":"5","key":"4207_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/00365513.2023.2227946","volume":"83","author":"Y Ding","year":"2023","unstructured":"Ding Y, Liu Z, Wang H, Xiong S, Zhai Z. Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia. Scand J Clin Lab Invest. 2023;83(5):340\u20137. https:\/\/doi.org\/10.1080\/00365513.2023.2227946.","journal-title":"Scand J Clin Lab Invest"},{"issue":"1","key":"4207_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1046\/j.1365-2141.2003.04552.x","volume":"123","author":"M Garg","year":"2003","unstructured":"Garg M, Moore H, Tobal K, Liu Yin JA. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol. 2003;123(1):49\u201359. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04552.x.","journal-title":"Br J Haematol"},{"issue":"10","key":"4207_CR25","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1200\/jco.2005.03.5303","volume":"24","author":"H Lapillonne","year":"2006","unstructured":"Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C, et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol. 2006;24(10):1507\u201315. https:\/\/doi.org\/10.1200\/jco.2005.03.5303.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4207_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00277-019-03808-6","volume":"99","author":"X-R Wang","year":"2020","unstructured":"Wang X-R, Chang Y, Yuan X-Y, Wang Y-Z, Qin Y-Z, Ruan G-R, et al. Overexpressed WT1 exhibits a specific immunophenotype in intermediate and poor cytogenetic risk acute myeloid leukemia. Ann Hematol. 2020;99(2):215\u201321. https:\/\/doi.org\/10.1007\/s00277-019-03808-6.","journal-title":"Ann Hematol"},{"issue":"2","key":"4207_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrc3002","volume":"11","author":"V Huff","year":"2011","unstructured":"Huff V. Wilms\u2019 tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer. 2011;11(2):111\u201321. https:\/\/doi.org\/10.1038\/nrc3002.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"4207_CR28","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/blood.V83.7.1876.1876","volume":"83","author":"M Sekiya","year":"1994","unstructured":"Sekiya M, Adachi M, Hinoda Y, Imai K, Yachi A. Downregulation of Wilms\u2019 tumor gene (wt1) during myelomonocytic differentiation in HL60 cells. Blood. 1994;83(7):1876\u201382.","journal-title":"Blood"},{"issue":"3","key":"4207_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.leukres.2006.05.022","volume":"31","author":"E Hernandez-Caballero","year":"2007","unstructured":"Hernandez-Caballero E, Mayani H, Montesinos JJ, Arenas D, Salamanca F, Pe\u00f1aloza R. In vitro leukemic cell differentiation and WT1 gene expression. Leuk Res. 2007;31(3):395\u20137. https:\/\/doi.org\/10.1016\/j.leukres.2006.05.022.","journal-title":"Leuk Res"},{"issue":"6","key":"4207_CR30","first-page":"677","volume":"5","author":"SA Phelan","year":"1994","unstructured":"Phelan SA, Lindberg C, Call KM. Wilms\u2019 tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. Cell Growth Differ. 1994;5(6):677\u201386.","journal-title":"Cell Growth Differ"},{"issue":"11","key":"4207_CR31","doi-asserted-by":"publisher","first-page":"1088.e1","DOI":"10.1016\/j.jtct.2024.08.008","volume":"30","author":"S Nakako","year":"2024","unstructured":"Nakako S, Okamura H, Yokota I, Umemoto Y, Horiuchi M, Sakatoku K, et al. Dynamic relapse prediction by peripheral blood wt1mrna after allogeneic hematopoietic cell transplantation for myeloid neoplasms. Transplant Cell Ther. 2024;30(11):1088.e1-e12. https:\/\/doi.org\/10.1016\/j.jtct.2024.08.008.","journal-title":"Transplant Cell Ther."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04207-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04207-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04207-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:04:38Z","timestamp":1785128678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04207-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4207"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04207-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Makuuchi received honoraria from Asahi Kasei Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, and SymBio Pharmaceuticals and research funding from CSL Behring. Dr. Kuno received honoraria from MSD, Asahi Kasei Pharma, CSL Behring, Nippon Shinyaku, Kyowa Kirin, Japan Blood Products Organization, Chugai Pharmaceutical, and Clarivate Analytics and research funding from Gilead Sciences, Nippon Medac, and Shionogi. Dr. Takakuwa received honoraria from AbbVie, ONO Pharmaceutical, Asclepia, Kyowa Kirin, Sanofi, SymBio Pharmaceuticals, Takeda, Chugai Pharmaceutical, Novartis, Fujimoto Pharmaceutical, Bristol-Myers Squibb, Janssen, PharmaEssentia, Meiji Seika Pharma, Genmab, GlaxoSmithKline, and Reno Medical and research funding from AbbVie, Incyte, GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Janssen, and Perseus Proteomics. Dr. Okamura received honoraria from ACADEMIC RESEARCH ORGANIZATION, Asahi Kasei Pharma, Nippon Shinyaku, Chugai Pharmaceutical, InterSystems, INTEC, Microsoft Japan, and Fujitsu Japan and research funding from Takeda, AstraZeneca, Chugai Pharmaceutical, and AICRO. Dr. Mika Nakamae received honoraria from H.U. Frontier and Novartis. Dr. Nishimoto received honoraria from CSL Behring, Takeda, Janssen, Asahi Kasei Pharma, Meiji Seika Pharma, Astellas, AbbVie, Daiichi Sankyo, and Nippon Shinyaku and research funding from Bayer, Zenyaku Kogyo, CSL Behring, and IQVIA. Dr. Nakashima received honoraria from MSD, Bristol-Myers Squibb, Astellas, JCR Pharmaceuticals, Eisai, Gilead Sciences, Daiichi Sankyo, Genmab, Amgen, Kyowa Kirin, Chugai Pharmaceutical, PharmaEssentia, and Janssen and research funding from ICON Clinical Research, MSD, Parexel, Astellas, AbbVie, Amgen, Novartis, and Bristol-Myers Squibb. Dr. Hirohisa Nakamae received honoraria from Astellas, AstraZeneca, AbbVie, Amgen, Otsuka, Kissei, Gilead Sciences, Sanofi, Genmab, Daiichi Sankyo, Takeda, Chugai, Nippon Shinyaku, Novartis, Bristol-Myers Squibb, Meiji Seika Pharma, and Janssen, and research funding from Astellas, AstraZeneca, Alexion, Incyte, CMIC, Takeda, Chugai, Novartis, Parexel, Bristol-Myers Squibb, Janssen, and the Japan Blood Products Organization. Dr. Hino received honoraria from Meiji Seika Pharma, Asahi Kasei Pharma, Astellas, AstraZeneca, AbbVie, Abbott, Amgen, Argenx, Alexion, Eisai, Otsuka, ONO Pharmaceutical, Kyowa Kirin, Gilead Sciences, Sanofi, Genmab, Daiichi Sankyo, Takeda, Chugai, Nippon Kayaku, Nippon Shinyaku, Novartis, PharmaEssentia, Pfizer, Bristol-Myers Squibb, Mallinckrodt, Mochida, Janssen, MSD and H.U. Frontier; research funding from Nippon Shinyaku, Bristol-Myers Squibb, Labcorp, and Sumitomo Pharma; and donations from JCR Pharmaceuticals, Asahi Kasei Pharma, Otsuka, Kyowa Kirin, Daiichi Sankyo, Chugai, Teijin, Japan Blood Products Organization, SEKISUI Medical, Sumitomo Pharma, Taiho, and Nippon Kayaku (none of which are related to the submitted work).","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki. This study was approved by the Osaka City University Graduate School of Medicine Ethics Committee (approval number: 2580.) All patients provided their written informed consent to participate in this study.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}